Acumen Pharmaceuticals In... (ABOS)
Acumen Pharmaceuticals Statistics
Share Statistics
Acumen Pharmaceuticals has 60.08M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 60.08M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 72.58% |
| Shares Floating | 43.92M |
| Failed to Deliver (FTD) Shares | 28 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.83M, so 3.04% of the outstanding shares have been sold short.
| Short Interest | 1.83M |
| Short % of Shares Out | 3.04% |
| Short % of Float | 4.17% |
| Short Ratio (days to cover) | 4.48 |
Valuation Ratios
The PE ratio is -3.56 and the forward PE ratio is -1.05. Acumen Pharmaceuticals's PEG ratio is -0.44.
| PE Ratio | -3.56 |
| Forward PE | -1.05 |
| PS Ratio | 0 |
| Forward PS | 2.9 |
| PB Ratio | 0.7 |
| P/FCF Ratio | -4.32 |
| PEG Ratio | -0.44 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acumen Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.01, with a Debt / Equity ratio of 0.11.
| Current Ratio | 19.01 |
| Quick Ratio | 19.01 |
| Debt / Equity | 0.11 |
| Total Debt / Capitalization | 9.64 |
| Cash Flow / Debt | -1.51 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -20.69%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.17% |
| Return on Capital (ROIC) | -20.69% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.03M |
| Employee Count | 51 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -72.63% in the last 52 weeks. The beta is -0.01, so Acumen Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.01 |
| 52-Week Price Change | -72.63% |
| 50-Day Moving Average | 1.6 |
| 200-Day Moving Average | 2.42 |
| Relative Strength Index (RSI) | 31.83 |
| Average Volume (20 Days) | 323.32K |
Income Statement
| Revenue | n/a |
| Gross Profit | -42.32M |
| Operating Income | -61.14M |
| Net Income | -52.37M |
| EBITDA | -51.61M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.08 |
Balance Sheet
The company has 66.89M in cash and 28.49M in debt, giving a net cash position of 38.4M.
| Cash & Cash Equivalents | 66.89M |
| Total Debt | 28.49M |
| Net Cash | 38.4M |
| Retained Earnings | -222.8M |
| Total Assets | 266.98M |
| Working Capital | 187.72M |
Cash Flow
In the last 12 months, operating cash flow was -43.06M and capital expenditures -21K, giving a free cash flow of -43.09M.
| Operating Cash Flow | -43.06M |
| Capital Expenditures | -21K |
| Free Cash Flow | -43.09M |
| FCF Per Share | -0.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -85.04% |
| FCF Yield | -56.25% |
Analyst Forecast
The average price target for ABOS is $7, which is 451.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 451.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -0.65 |
| Piotroski F-Score | 2 |